This article was originally published in The Gray Sheet
Executive SummaryPhase III clinical trials for its intraocular Implantable Contact Lens for the treatment of myopia will begin following FDA go ahead. Staar, which so far has tested the ICL in 80 eyes, may now implant another 278 IOLs, while increasing the number of sites to 15, the company says. The Monrovia, California-based firm also may expand its study to treat patients with as little as -3 diopters of refractive error and reduce the waiting period for patients to receive an IOL in the second eye to 45 days from six months
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.